CAR-NK Therapy Development Service

Chimeric antigen receptor natural killer cells (CAR-NK cells) therapy is one arising types of immunotherapy that harnesses the power of natural killer cells to destroy targeted cells without the need for prior exposure or activation. Our company provides cutting-edge research services to help you rapidly design and develop CAR-NK cell therapies with high efficacy for Autoimmune Diseases & Inflammation.

CAR-NK Therapy in Autoimmune Diseases & Inflammation

CAR-NK cell is a kind of innate lymphoid cells with natural killing ability independent of antigen specific recognition, which plays a pivotal role in autoimmunity and inflammation due to their natural cytotoxicity and migration ability by the production of cytokines and chemokines. The NK cells are widely present in circulatory system, lymph nodes and some solid tissues, and participate in rapid regulation of immune response globally or locally.

The functional involvement of NK cells is more sophisticated in autoimmune context than in infection or tumors, as the diversity of receptors and ligands on the surface of NK cells allows them to recognize and contact a variety of cell types, including immune cells, to induce caspase-dependent apoptosis in organ-specific or systemic patterns in autoimmune diseases.

Fig.1 Therapeutic potential of NK-based therapy in autoimmune disorders (Yang Y., et al., 2021)

Whereas CAR-NK cell therapy in some therapeutics cases may cause unique toxicities associated with cytokine release syndrome and encephalopathy syndrome, CAR-NK cell therapy has shown multiple advantages in both laboratory studies and clinical outcomes with a safer profile, making it a potential alternative for autoimmune diseases.

• Simple Cytokines Spectrum. Activated NK cells secreted relatively simple cytokines, including IFN-g and GM-CSF, which reduce tissue damage caused by persistent pro-inflammatory cytokines.
• Dual Mechanism of Action. In addition to eliminating targeted cells through the CAR-modification, NK cells possess the inherent cytotoxic activity by numerous CAR-independent manners to disintegrate the cells without CAR-targeted antigen.
• Multiple Sources. CAR-NK cells can be generated from peripheral blood, placenta and cord blood, established cell line NK92 and iPSCs to produce pre-made allogeneic stable products, without the requisite to be patient specific.

These properties allow CAR-NK to be immediately incorporated into interventions to reduce excessive immune responses. In addition, when combined with other types of therapeutics, such as therapeutic antibodies, CAR-NK cells, chemotherapy, etc., it can further improve the durable therapeutics of Autoimmune Diseases & Inflammation.

Our Services

CAR-NK cell therapy combined CAR technology with the properties of NK cells has been shown great potential in research for Autoimmune Diseases & Inflammation. Our company provides leading-edge therapeutic cell services for CAR-NK cell therapy development as the following workflow:

We provide the CAR design services for targets including but not limited to:

Our Advantages

Supported by experienced senior researchers specializing in molecular biology and cell engineering, and equipped with a comprehensive cell engineering experimental platform, our company is dedicated to providing considerate services to facilitate the development of therapeutic CAR-NK cells for Autoimmune Diseases & Inflammation. Please contact us for more detailed information and our team will get back to you promptly.

Reference

1. Yang, Yuyan et al. "Natural killer cells in inflammatory autoimmune diseases." Clinical & translational immunology 10,2 (2021): e1250.